Back to top
more

Poseida Therapeutics (PSTX)

(Delayed Data from NSDQ)

$2.32 USD

2.32
324,356

+0.19 (8.92%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $2.32 0.00 (0.00%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adaptimmune (ADAP) Down on End of Collaboration With Roche

by Zacks Equity Research

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 25% and 99.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Universal Health Services (UHS) delivered earnings and revenue surprises of 3.64% and 1.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 12.50% and 67.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 19.35% and 16.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 13.56% and 142.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -12.50% and 3.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's What Could Help Poseida Therapeutics, Inc. (PSTX) Maintain Its Recent Price Strength

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.

Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label

by Zacks Equity Research

The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.

Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.